Drugs / SK08
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07021157 | Mar → Aug 2025 overdue | chronic kidney disease | Consun Pharmaceutical Group | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06725017 | Jul 2025 → Jul 2027 expected | ulcerative colitis | Guangzhou Zhiyi Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06247046 | Mar 2024 → Apr 2026 overdue | irritable bowel syndrome | Guangzhou Zhiyi Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK-08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07021157 ↗ |
| Known as | Live SK08 powder | “Live SK08 powder” NCT06725017 ↗ |
| Action | Activate | “induced dose-related sGC activation.” PMID 42426639 ↗ Jul 2026 |
| Modality | Other / unclassified | “live biotherapeutic product” NCT06725017 ↗ |
| Route | Oral | “Live SK08 powder, (1-25)×10^9 CFU, oral, twice daily for up to 52 weeks period.” NCT06247046 ↗ |